SynthesisJournal of psychopharmacology (Oxford, England)2023
Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder.
Synthesis in Journal of psychopharmacology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.Journal of psychiatric research · 2023Trial
- Understanding experiences of psychedelic treatments for eating disorders: a meta-synthesis of qualitative studies.BMC medicine · 2026Review
- Body image phenomenology in reports of psychedelic and meditative experiences: main themes and associations with body attitudes.Neuroscience of consciousness · 2026Article
- Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa.Journal of eating disorders · 2025Article
- Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond.ACS pharmacology & translational science · 2025Review
- Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design.Journal of eating disorders · 2024Review
- Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.Nature. Mental health · 2024Article
- Psychedelics and the treatment of eating disorders: considerations for future research and practice.Journal of eating disorders · 2024Article
- Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024Review
- Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence.Trends in psychiatry and psychotherapy · 2024Review
- The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression.Frontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundClinical use of psychedelics has gained considerable attention, with promising benefits across a range of mental disorders. Current pharmacological and psychotherapeutic treatments for body dysmorphic disorder (BDD) and eating disorders (EDs) have limited efficacy. As such, other treatment options such as psychedelic-assisted therapies are being explored in these clinical groups.
aimsThis systematic review evaluates evidence related to the therapeutic potential of psychedelics in individuals diagnosed with BDD and EDs.
methodsFollowing Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic review of all study designs published to the end of February 2022 that identified changes in ED/BDD symptom severity from psychedelics using validated measures to assess symptom changes.
resultsOur search detected a total of 372 studies, of which five met inclusion criteria (two exploratory studies, two case reports, and one prospective study). These were included in the data evaluation. Effects of psychedelics on BDD and various ED symptoms were identified mostly through thematic analyses and self-reports.
conclusionsOur findings highlight that more research is needed to determine the safety and efficacy of psychedelics in BDD and EDs and we suggest avenues for future exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.